ArticleBreast cancer research : BCR2019

A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.

Ronan P McLaughlin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.